Dyax Corp. Reports Senior Management Changes

26-Jan-2005

Dyax Corp. announced that Anthony H. Williams, FCRP, Senior Vice President of Medical Affairs and Clinical Operations, has resigned from Dyax in order to accept a senior clinical oncology position with a major pharmaceutical company. Dr. Williams will remain available to Dyax as a consultant during a transition period.

Dyax also announced that it has engaged two industry experts to assist with its heightened focus on clinical and regulatory activities involving its lead compound DX-88. The first, Thomas R. Beck, M.D., a licensed physician with over twenty years of pharmaceutical and biotech industry experience, particularly in the area of clinical development, is joining Dyax in an interim management role. The clinical and regulatory departments at Dyax will report to Dr. Beck until Dr. Williams' full-time successor is identified. The second, William D. Schwieterman, M.D., a veteran of the National Institutes of Health (NIH) and previous Chief of the Immunology and Infectious Disease branch of the Center for Biologics Evaluation and Research at the US Food and Drug Administration (FDA), will provide regulatory advisory services to Dyax.

Henry Blair, Dyax's President and Chief Executive Officer, stated "We will immediately begin a thorough process to identify Dr. Williams' successor. In the meantime, we have very capable clinical and regulatory staff at Dyax who remain focused on the successful implementation of our development and commercialization plans. Their efforts, along with the involvement of Drs. Beck and Schwieterman, will facilitate a smooth transition as we proceed with our plans to initiate new clinical trials in CABG and HAE."

https://www.bionity.com/en/news/42825/dyax-corp-reports-senior-management-changes.html